Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06487013

Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study

Led by EpiSonica · Updated on 2024-07-05

100

Participants Needed

4

Research Sites

94 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Pivotal Study to Evaluate the Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases

CONDITIONS

Official Title

Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 18 and older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at enrollment
  • Able and willing to give consent and attend all study visits
  • Suffering from painful bone metastases
  • Refuse other accepted treatments such as surgery or radiotherapy for pain palliation
  • Pain score of 4 or higher on the NRS (0-10 scale) regardless of medication
  • Able to communicate sensations during ArcBlate MRgHIFU treatment
  • On stable systemic anticancer treatment for at least 2 weeks before treatment
  • No radiation therapy to targeted lesion in the past two weeks before treatment
  • Stable bisphosphonate intake throughout the study
  • Have 1 to 5 painful lesions; only the most painful lesion will be treated
  • Persistent distinguishable pain at one treatment site, with pain from other sites at least 2 points less intense on the NRS
  • Targeted tumors accessible by ArcBlate MRgHIFU and located in ribs, extremities (excluding joints), pelvis, shoulders, or specified spinal vertebrae
  • Target lesion on bone with bone-lesion interface deeper than 10 mm from the skin
  • Target lesion clearly visible by non-contrast MRI and accessible by ArcBlate MRgHIFU
  • Able to tolerate planned test sonications during treatment
Not Eligible

You will not qualify if you...

  • Need surgical stabilization of affected bone (fracture risk score >7) or have surgical stabilization with metallic hardware
  • Targeted lesion located in the skull
  • Patients on dialysis
  • Life expectancy less than 3 months
  • Acute medical conditions hindering study completion (e.g., pneumonia, sepsis)
  • Unstable cardiac conditions including unstable angina, recent myocardial infarction (within 6 months), congestive heart failure requiring medication, or use of anti-arrhythmic drugs
  • Severe hypertension (diastolic BP >100 mmHg on medication)
  • Standard contraindications for MRI such as non-MRI compatible implanted devices or size limitations
  • Active infection or severe uncontrolled hematological, neurological, or other diseases
  • Known allergies or intolerance to MRI or CT contrast agents
  • Severe cerebrovascular disease (multiple strokes or stroke within 6 months)
  • Unable or unwilling to tolerate prolonged stationary position during treatment (~2 hours)
  • Participation in another clinical trial within the last 30 days
  • Initiation of new chemotherapy or radiation to target lesion within 2 weeks before treatment
  • Unable to communicate with study staff
  • Persistent undistinguishable pain source
  • Target lesion pain not at least 2 points higher than other painful lesions on NRS
  • Calcified treatment area
  • Pregnancy
  • Target lesion less than 10 mm from nerve bundles, bowels, or bladder
  • Extensive scarring in the treatment energy path

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Far Eastern Memorial Hospital

New Taipei City, Taiwan, 220

Not Yet Recruiting

2

Taichung Veterans General Hospital

Taichung, Taiwan, 407

Actively Recruiting

3

National Taiwan University Hospital

Taipei, Taiwan, 100

Not Yet Recruiting

4

Chang Gung Memorial Hospital - Linkou

Taoyuan, Taiwan, 333

Not Yet Recruiting

Loading map...

Research Team

F

Feng-Xian Yan

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here